Dacryocystitis stent

Abstract

The invention provides a dacryocystitis stent which is used for being supported at an anastomotic stoma after nasal anastomosis, the dacryocystitis stent is of a T-shaped structure, the T-shaped structure stent comprises a transverse stent body and a longitudinal stent body, the transverse stent body is communicated with the longitudinal stent body, the transverse stent body is used for being implanted in the nasolacrimal duct, and the longitudinal stent body is used for being implanted in the nasolacrimal duct. The longitudinal support is used for being implanted in the position of the anastomotic stoma. Therefore, the T-shaped structure support is arranged at the part of the nasolacrimal duct and the lacrimal sac cavity and is more fit with the physical shape of the lacrimal passage, so that the whole T-shaped structure support is not easy to fall off, and an anastomotic stoma and a mucosal flap formed after a nasal cavity lacrimal sac anastomosis operation are more stably supported; the transverse support part of the T-shaped structure support can support the interior of the nasolacrimal duct, the longitudinal part of the T-shaped structure support supports the anastomotic stoma, and the whole lacrimal passage is smoother.

Description

Technical Field

[0001] This invention relates to the field of medical device technology, and in particular to a stent for dacryocystitis. Background Technology

[0002] Chronic dacryocystitis is a common eye disease, mostly caused by narrowing or complete blockage of the lacrimal duct, leading to impaired tear drainage. The long-term retention of tears in the lacrimal sac causes bacterial growth, resulting in inflammation.

[0003] Chronic dacryocystitis is primarily treated with endoscopic dacryocystorhinostomy (DCR). This procedure involves opening the nasal cavity and lacrimal sac to create a dacryocystorhinostomy, forming a new channel that allows tears to drain directly into the nasal cavity through the newly opened anastomosis, bypassing the nasolacrimal duct. However, a challenge of DCR lies in the tendency for implanted instruments to dislodge, making it difficult to properly fix and align the anastomotic mucosal flap. Improper fixation or alignment of the anastomotic mucosal flap can lead to reclosure of the anastomosis, resulting in surgical failure.

[0004] Meanwhile, most lacrimal duct drainage uses silicone tubes, which have the following drawbacks: (1) When implanting the lacrimal duct drainage tube, it needs to be inserted from the patient's upper / lower lacrimal punctum, through the upper / lower lacrimal canaliculi, common lacrimal duct, naso-dacryocystorhinostomy, and out through the nasal cavity, and then the drainage tube is tied to prevent it from falling out. The implantation method is relatively complicated. It may also damage the patient's originally intact lacrimal duct; (2) The material of the lacrimal duct drainage tube is relatively soft, and the radial support for the anastomosis is poor, so it cannot fix the mucosal flap; (3) It does not carry drugs and cannot perform targeted drug therapy. Long-term (3-4 months) retention in the naso-dacryocystorhinostomy may lead to infection, stimulate the formation of mucosal granulation tissue and scars, and may even cause the anastomosis to be obstructed or even closed; (4) Silicone material is non-degradable and requires a second surgery to remove. After a long period of contact with the lacrimal duct, some mucosa has adhered to the tube. When the tube is removed in a second surgery, it will cause secondary damage to the already healed surgical site.

[0005] Therefore, developing a method that is not easily dislodged, can support the anastomosis, and achieve stable fixation of the mucosal flap is an urgent problem to be solved. Summary of the Invention

[0006] The purpose of this invention is to provide a dacryocystitis stent to solve the technical problems of existing implantable devices being prone to dislodgement, failing to provide adequate support for the anastomosis, and failing to achieve fixation of the mucosal flap.

[0007] To address the aforementioned technical problems, the present invention provides a dacryocystitis stent for supporting the anastomosis site after nasal cavity anastomosis. The dacryocystitis stent is a T-shaped structure stent, which includes a transverse stent and a longitudinal stent. The transverse stent and the longitudinal stent communicate with each other. The transverse stent is used for implantation at the site of the nasolacrimal duct, and the longitudinal stent is used for implantation at the site of the anastomosis.

[0008] Optionally, the transverse support and the longitudinal support are integrally formed.

[0009] Optionally, the diameter of the transverse support is 10-15mm, the length of the transverse support is 5-20mm, the diameter of the longitudinal support is 5-10mm, and the length of the longitudinal support is 5-10mm.

[0010] Optionally, the number of vertices of the transverse and longitudinal supports is 5-11, the number of intersections of the transverse and longitudinal supports is 2-3, and the diameter of the filaments of the dacryocystitis support is 0.1-0.5 mm.

[0011] Optionally, the radial dimension of the transverse support is greater than the radial dimension of the nasolacrimal duct, and the radial dimension of the longitudinal support is greater than the size of the anastomosis.

[0012] Optionally, the dacryocystitis stent is made of a biodegradable material, and the support of the dacryocystitis stent is maintained for 3-60 days; the biodegradable material includes: polylactic acid, polybutylene adipate / terephthalate, polybutylene succinate, polybutylene adipate, polycaprolactone, polypropylene carbonate, polyglycolic acid, or polydioxanone; or blends of polylactic acid, polybutylene adipate / terephthalate, polybutylene succinate, polybutylene adipate, polycaprolactone, polypropylene carbonate, polyglycolic acid, or polydioxanone, or copolymers thereof, or homologues thereof.

[0013] Optionally, the dacryocystitis stent has a stent body and a drug-releasing layer, the drug-releasing layer comprising a drug, the drug-releasing layer being attached to the outside of the stent body to achieve sustained release; the drug release period of the drug-releasing layer is longer than the wound healing time at the anastomosis site; the drug release period of the drug-releasing layer is less than two months; the drug-releasing layer is ultrasonically sprayed; the drug includes prednisone, methylprednisone, betamethasone, beclomethasone propionate, prednisolone, hydrocortisone, dexamethasone, or mometasone furoate, or the drug is a combination of prednisone, methylprednisone, betamethasone, beclomethasone propionate, prednisolone, hydrocortisone, dexamethasone, or mometasone furoate.

[0014] Optionally, the drug sustained-release layer includes a drug and a biodegradable polymer, wherein the drug is one or more drugs, and when there are multiple drugs, the different drugs have different or the same sustained-release period; the biodegradable polymer is a biodegradable material or a mixture of multiple biodegradable materials.

[0015] This invention provides a dacryocystitis stent for supporting the anastomosis site after nasolacrimal duct anastomosis. The stent is T-shaped, comprising a transverse stent and a longitudinal stent, which communicate with each other. The transverse stent is implanted into the nasolacrimal duct, and the longitudinal stent is implanted into the anastomosis site. This T-shaped stent, positioned within the nasolacrimal duct and lacrimal sac cavity, better conforms to the physical shape of the lacrimal duct, making it less prone to dislodgement and providing more stable support for the anastomosis and mucosal flap formed after nasolacrimal duct anastomosis. The transverse stent portion of the T-shaped stent supports the interior of the nasolacrimal duct, while the longitudinal portion supports the anastomosis site, resulting in better overall lacrimal duct patency. Attached Figure Description

[0016] Those skilled in the art will understand that the accompanying drawings are provided to better understand the invention and do not constitute any limitation on the scope of the invention. Wherein:

[0017] Figure 1 This is a perspective view of the dacryocystitis stent provided in an embodiment of the present invention.

[0018] Figure 2 This is an anatomical diagram of the dacryocystitis stent implanted in an embodiment of the present invention.

[0019] In the attached image:

[0020] 10-Dacryocystitis stent, 11-Transverse stent, 12-Longitudinal stent. Detailed Implementation

[0021] To make the objectives, advantages, and features of the present invention clearer, the present invention will be further described in detail below with reference to the accompanying drawings and specific embodiments. It should be noted that the drawings are all in a very simplified form and are not drawn to scale, and are only used to facilitate and clearly illustrate the objectives of the embodiments of the present invention.

[0022] As used herein, the singular forms “a,” “an,” and “the” include plural objects unless otherwise expressly indicated. As used herein, the term “or” is generally used to include the meaning of “and / or” unless otherwise expressly indicated. Furthermore, numerous specific details are set forth in the following description to provide a more thorough understanding of the invention. However, it will be apparent to those skilled in the art that the invention can be practiced without one or more of these details. It should be noted that the following detailed description is illustrative and intended to provide further explanation of the application. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application pertains.

[0023] This invention provides a dacryocystitis stent for supporting the anastomosis site after nasolacrimal duct anastomosis. The stent is T-shaped, comprising a transverse stent and a longitudinal stent, which communicate with each other. The transverse stent is implanted into the nasolacrimal duct, and the longitudinal stent is implanted into the anastomosis site. This T-shaped stent, positioned between the nasolacrimal duct and the lacrimal sac cavity, better conforms to the physical shape of the lacrimal duct, making it less prone to dislodgement and providing more stable support for the anastomosis and mucosal flap formed after nasolacrimal duct anastomosis. The transverse stent portion of the T-shaped stent supports the interior of the nasolacrimal duct, while the longitudinal portion supports the anastomosis site, resulting in better overall lacrimal duct patency.

[0024] The following will describe this embodiment in detail.

[0025] Figure 1 A perspective view of the dacryocystitis stent provided in an embodiment of the present invention; Figure 2 This is an anatomical diagram of the dacryocystitis stent implanted in an embodiment of the present invention.

[0026] like Figure 1 and Figure 2 As shown, this embodiment provides a dacryocystitis stent for supporting the anastomosis site after nasolacrimal anastomosis. The dacryocystitis stent is a T-shaped structure stent, comprising a transverse stent and a longitudinal stent, which communicate with each other. The transverse stent is implanted into the nasolacrimal duct, and the longitudinal stent is implanted into the anastomosis site. Thus, the T-shaped stent, positioned between the nasolacrimal duct and the lacrimal sac cavity, better conforms to the physical shape of the lacrimal duct, making it less prone to dislodgement and providing more stable support for the anastomosis and mucosal flap formed after nasolacrimal anastomosis. The transverse stent portion of the T-shaped stent supports the interior of the nasolacrimal duct, while the longitudinal portion supports the anastomosis site, resulting in a more unobstructed lacrimal duct overall.

[0027] Preferably, the transverse support and the longitudinal support are integrally formed, which can make the structure of the dacryocystitis support more stable.

[0028] Preferably, in the naturally released state, the diameter of the transverse support is 10-15 mm, for example, 10, 11, 12, 13, 14, or 15 mm. The length of the transverse support is 5-20 mm, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mm. The diameter of the longitudinal support is 5-10 mm, for example, 5, 6, 7, 8, 9, or 10 mm, and the length of the longitudinal support is 5-10 mm, for example, 5, 6, 7, 8, 9, or 10 mm.

[0029] Preferably, the number of vertices of the transverse and longitudinal supports is 5-11, for example, 5, 6, 7, 8, 9, 10, or 11. The number of vertices indicates the density of the dacryocystitis support 10, and this density can directly provide different levels of support to the common lacrimal duct. The number of intersections between the transverse and longitudinal supports is 2-3, for example, 2 or 3. The diameter of the filaments in the dacryocystitis support is 0.1-0.5 mm, for example, 0.1, 0.2, 0.3, 0.4, or 0.5 mm.

[0030] Preferably, the radial dimension of the transverse support is greater than the radial dimension of the nasolacrimal duct, and the radial dimension of the longitudinal support is greater than the size of the anastomosis, thereby allowing the dacryocystitis stent to open the nasolacrimal duct, lacrimal sac, and anastomosis.

[0031] Optionally, the dacryocystitis stent is made of a biodegradable material, and the support of the dacryocystitis stent is maintained for 3-60 days; the biodegradable material includes: polylactic acid, polybutylene adipate / terephthalate, polybutylene succinate, polybutylene adipate, polycaprolactone, polypropylene carbonate, polyglycolic acid, or polydioxanone; or blends of polylactic acid, polybutylene adipate / terephthalate, polybutylene succinate, polybutylene adipate, polycaprolactone, polypropylene carbonate, polyglycolic acid, or polydioxanone, or copolymers thereof, or homologues thereof. The biodegradable dacryocystitis stent can degrade within two months and will not remain in the nasolacrimal duct and anastomosis for a long time. It will not cause secondary infection due to long-term retention, stimulate the formation of mucosal granulation tissue and scars, and avoid the situation where the anastomosis becomes obstructed or even closed again due to granulation tissue and scars.

[0032] Optionally, the dacryocystitis stent has a stent body and a drug-releasing layer. The drug-releasing layer includes a drug, which is attached to the outside of the stent body to achieve sustained release. The drug release period of the drug-releasing layer is longer than the wound healing time at the anastomosis site. The drug release period of the drug-releasing layer is less than two months. The drug-releasing layer is ultrasonically sprayed. The drug includes prednisone, methylprednisone, betamethasone, beclomethasone dipropionate, prednisolone, hydrocortisone, dexamethasone, or mometasone furoate, or the drug is a combination of prednisone, methylprednisone, betamethasone, beclomethasone dipropionate, prednisolone, hydrocortisone, dexamethasone, or mometasone furoate. This allows the drug to directly diffuse to the anastomosis site, be absorbed by the surgical site, and directly contact the lesion site over a large area, achieving targeted drug delivery and improving the efficiency of drug treatment. The treatment effect is good, avoiding the harm of oral administration or re-implantation of drugs, and postoperative nasal spray treatment is not required. The medication may have antibacterial, anti-inflammatory, or anti-granulation scar properties, thereby inhibiting the growth of scars at the anastomosis site, ensuring that the anastomosis can heal as soon as possible, and maintaining long-term patency of the lacrimal duct.

[0033] Preferably, the drug sustained-release layer comprises a drug and a biodegradable polymer, wherein the drug is one or more drugs, and when there are multiple drugs, different drugs have different or the same sustained-release period; the biodegradable polymer is a biodegradable material or a mixture of multiple biodegradable materials. This configuration allows for more choices of materials for the dacryocystitis stent, and different adaptable materials can be selected according to different degradation times.

[0034] In summary, the present invention provides a dacryocystitis stent for supporting the anastomosis site after nasolacrimal anastomosis. The dacryocystitis stent is a T-shaped structure, comprising a transverse stent and a longitudinal stent, which communicate with each other. The transverse stent is implanted into the nasolacrimal duct, and the longitudinal stent is implanted into the anastomosis site. Thus, the T-shaped stent, positioned between the nasolacrimal duct and the lacrimal sac cavity, better conforms to the physical shape of the lacrimal duct, making it less prone to dislodgement and providing more stable support for the anastomosis and mucosal flap formed after nasolacrimal anastomosis. The transverse stent portion of the T-shaped stent supports the interior of the nasolacrimal duct, while the longitudinal portion supports the anastomosis site, resulting in a more unobstructed lacrimal duct overall. This dacryocystitis stent is suitable for treating the anastomosis site after dacryocystorhinostomy in patients with chronic dacryocystitis. It provides excellent support for the dacryocystorhinostomy site, and its mechanical support helps to fix the anastomosis, promoting good adhesion and healing of the mucosal flap and wound. This eliminates the need for clinicians to perform sutures to fix and repair the mucosal flap in a confined space. The stent offers minimal foreign body sensation and good post-implantation comfort. It allows for targeted drug treatment of the lesion site, providing large-area, all-around direct contact with the lesion, eliminating the need for post-operative nasal spray treatment. Furthermore, the stent is completely biodegradable, requiring no further removal after surgery, avoiding repeated visits and preventing secondary damage to the surgical site.

[0035] The above description is merely a description of preferred embodiments of the present invention and is not intended to limit the scope of the present invention in any way. Any changes or modifications made by those skilled in the art based on the above disclosure shall fall within the protection scope of the claims.

Claims

1. A stent for dacryocystitis, characterized in that, The dacryocystitis stent is a T-shaped structure stent used to support the anastomosis site after nasal cavity anastomosis. The T-shaped structure stent includes a transverse stent and a longitudinal stent, which are connected. The transverse stent is used to be implanted at the site of the nasolacrimal duct, and the longitudinal stent is used to be implanted at the site of the anastomosis.

2. The dacryocystitis stent according to claim 1, characterized in that, The horizontal support and the vertical support are integrally formed.

3. The dacryocystitis stent according to claim 1, characterized in that, The diameter of the horizontal support is 10-15mm, the length of the horizontal support is 5-20mm, the diameter of the vertical support is 5-10mm, and the length of the vertical support is 5-10mm.

4. The dacryocystitis stent according to claim 1, characterized in that, The number of vertices of the horizontal and vertical supports is 5-11, the number of intersections of the horizontal and vertical supports is 2-3, and the diameter of the filaments of the dacryocystitis support is 0.1-0.5 mm.

5. The dacryocystitis stent according to claim 1, characterized in that, The radial dimension of the transverse support is greater than the radial dimension of the nasolacrimal duct, and the radial dimension of the longitudinal support is greater than the size of the anastomosis.

6. The dacryocystitis stent according to claim 1, characterized in that, The dacryocystitis stent is made of biodegradable material, and the support force of the dacryocystitis stent is maintained for 3-60 days. The biodegradable materials include: polylactic acid, polybutylene adipate / terephthalate, polybutylene succinate, polybutylene adipate-succinate, polycaprolactone, polypropylene carbonate, polyglycolic acid, or polydioxanone; or blends, copolymers, or homologues of polylactic acid, polybutylene adipate / terephthalate, polybutylene succinate, polybutylene adipate-succinate, polycaprolactone, polypropylene carbonate, polyglycolic acid, or polydioxanone.

7. The dacryocystitis stent according to claim 1, characterized in that, The dacryocystitis stent has a stent body and a drug-releasing layer, the drug-releasing layer comprising a drug, and the drug-releasing layer is attached to the outside of the stent body to achieve sustained release; The drug release period of the sustained-release layer is longer than the wound healing time at the anastomosis site. The drug release period of the sustained-release layer is less than two months; The drug sustained-release layer is applied by ultrasonic spraying; The drug includes prednisone, methylprednisone, betamethasone, beclomethasone propionate, prednisolone, hydrocortisone, dexamethasone, or mometasone furoate, or the drug is a combination of prednisone, methylprednisone, betamethasone, beclomethasone propionate, prednisolone, hydrocortisone, dexamethasone, or mometasone furoate.

8. The dacryocystitis stent according to claim 7, characterized in that, The drug sustained-release layer comprises a drug and a biodegradable polymer, wherein the drug is one or more drugs, and when there are multiple drugs, the different drugs have different or the same sustained-release period; the biodegradable polymer is a biodegradable material or a mixture of multiple biodegradable materials.

Images